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Abstract
Radiation therapy in patients with head and neck cancer has a toxic effect on mucosa,
the soft tissue in and around the mouth. Hence mucositis is a serious common side effect
and is a condition characterized by pain and inflammation of the surface of the mucosa.
Although the mucosa recovers during breaks of and following the radiotherapy course the
recovery will depend on the type of tissue involved and on its location. Statistical models
used in oncology for analysing oral mucositis are often too simplistic and there is a need
for improved statistical methods in order to help improve planning of radiation therapy. We
∗contributed equally to this work.
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present a novel flexible multivariate random effects proportional odds model which takes
account of the longitudinal course of oral mucositis at different mouth sites and of the radi-
ation dosage (in terms of cumulative dose). The model is an extension of the proportional
odds model which is used for ordinal response variables. Our model includes the ordinal
multivariate response of the mucositis score by location, random intercepts for individuals
and includes a non-linear function of cumulative radiation dose. The model allows to test
whether sensitivity differs by mouth sites after having adjusted for site specific cumulative
radiation dose. The model also allows to check whether and how the (non-linear) effect
of site specific dose differs by site. We fit the model to longitudinal patient data from a
prospective observation and find that after adjusting for cumulative dose, upper, lower lips
and mouth floor are associated with the lowest mucositis scores and hard and soft palate
are associated with the highest mucositis scores. This implies the possibility that tissues at
different mouth locations differ in their sensitivity to the toxic effect of radiation. We also
find that cumulative dose followed by mouth site are the strongest predictors of mucositis,
and the effects of age and gender are negligible.
Keywords: generalised additive mixed model, proportional odds model, cumulative threshold
model, radiation therapy, multivariate repeated measures, ordered categorical response, biolog-
ically effective dose (BED), mucositis.
1 Introduction
Radiation therapy in patients with head and neck cancer has a toxic effect on mucosa, the soft
tissue in and around the mouth. Hence mucositis is a common side effect and is a condition
characterized by pain and inflammation of the surface of the mucosa. Mucositis causes serious
oral pain which makes the food intake of the cancer patients painful. It is known that mucositis is
in general developed 14 days after starting radiotherapy. Although the mucosa recovers during
breaks of and following the radiotherapy course the recovery will depend on the type of tissue
involved and on its location. Hence there is a need to quantify the damage to the mucosa by
different mouth sites. Here the clinical objective is in assessing the sensitivity to radiation of
different mouth sites in order to improve planning of radiation therapy to avoid these side effects.
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To obtain clinical evidence observational data were collected on a total of 75 patients receiving
radiation therapy between September 2006 and February 2012. During the course of radiation
therapy mucositis was assessed in 8 mouth sites approximately twice a week. For assessment
an ordinal severity score with 5 levels was used, ranging from 0 (no change in tissue) to 4
(necrosis). At each assessment cumulative dose and the median value of the percentage site
specific dose was recorded, so that the site specific cumulative dose could be derived. In addition
all relevant patient characteristics were recorded.
Statistical analyses on oral mucositis as an adverse effect of therapy are often simplistic. For
example Sakellari et al. [13] analyse oral mucositis in patients after high-dose chemotherapy
using logistic regression of cumulative incidence of mucositis. The approach neglects the time
course of the disease (oral mucositis), the fact the end-point is ordinal and the dosage of the
chemotherapy.
Our aim is to answer the clinical question by modelling the outcome variable mucositis score as
a function of patient specific variables and (site) specific cumulative dose. Then the sensitivity
of different mouth sites to radiation therapy can be assessed by estimating the effect of mouth
sites on the mucositis score, after adjusting for confounder variables, the most obvious being
site specific cumulative dose. Due to the observational nature of the data we need to adjust for
confounder variables.
These longitudinal data on the course of mucositis and cumulative dose of radiation therapy
have a complex structure and pose a number of statistical challenges:
(1) the outcome is ordinal; (2) We have a multivariate outcome variable, as we have mucositis
scores assessed for eight different sites per patient and time points (evaluation); (3) the outcome
is longitudinal and we expect that repeated observations of individuals are correlated; (4) due to
the fact that the mucosa can recover during radiation breaks a non-linear effect of sites specific
cumulative dose on the mucositis score is plausible. (5) Finally, it is also likely that the effect
of site specific dose differs by site, i.e. there is an interaction between site and site specific
dose. We address these challenges with a flexible multivariate random effects proportional odds
model. This is an extension of the proportional odds model [11] which is used for ordinal
response variables and belongs to the class of generalized linear models used for modelling
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the dependence of an ordinal response on discrete or continuous covariates. The model is an
extension of the multivariate random effects models for longitudinal data described in Verbeke
et al. [15]. See also Faraway [7] and Agresti [1] for some recent expositions of ordinal response
models.
2 The data
Observational data were collected on a total of 75 patients receiving radiation therapy for head
and neck cancer between September 2006 and February 2012 in the Radiation Oncology De-
partment, Medical Center, University of Freiburg. Three-dimensional radiation planning tech-
niques and standard fractionation (5 x 2.0 Gy/wk) were followed. The total dose to the tumour
was 60 Gy to 70 Gy. Radiation breaks were not allowed. Additional cisplatin 100 mg/m2 was
given intravenously on days 1 and 22 (and on day 43 for patients undergoing primary definitive
radiation or with residual cancer following surgery). The oral mucosa was evaluated in eight
mouth sites (upper lip, lower lip, floor of mouth, right cheek, left cheek, tongue, soft palate hard
palate) by using the five level NIH-CTC oral toxicity scale ((0) no mucositis, (1) erythema, (2)
ulcer, (3) confluent ulcer, (4) necrosis). Twice-weekly assessments (at least 3 days apart) con-
tinued throughout radiotherapy and then until resolution of oral mucositis. At each assessment
the cumulative dose to the tumor and the median value of the percentage of the site specific dose
was recorded, so that the site specific cumulative dose could be derived. In addition all relevant
patient characteristics were recorded. All study procedures were reviewed by the local ethics
committee and all patients provided written consent.
The mucositis progressions on eight different sites of four randomly sampled patients are de-
picted in Figure 1, showing the ordinal scale of mucositis scores as well as longitudinal multi-
variate structure.
Our main goal is to investigate the relationship between mucositis progression and potential
risk factors. Let yi jl be the mucositis score for individual i = 1, . . . , 75, evaluation j = 1, . . . , ni
and site l = 1, . . . , 8. This gives a total number of 7314 observations (75 patients × 8 sites ×
12.23 the mean number of evaluations per patient). The risk factors are patient characteristics
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Figure 1: Each row shows mucositis progression for one of four randomly selected individuals
on 8 mouth sites (hard palate, soft palate, tongue, mouth floor, upper lip, lower lip, left
cheek, right cheek); the same color indicates the same site.
(sexi and agei), sitel (hard palate, soft palate, tongue, mouth floor, upper lip, lower lip, left
cheek, right cheek), cumulative (radiation) dose (cumdosei j), median percentage dose of the
site (percil), the site specific cumulative dose cumdos.sitei jl and the site specific volumeil.
The site specific dose cumdos.sitei jl at evaluation j is determined by multiplying the total
cumulative dose cumdosei j with the median percentage dose of the site (percil). The median
percentage dose per site (percil) is assumed to be constant over time as it is the median per-
centage of cumdosei j at the site receiving radiation over the entire radiation schedule. Apart
for some exceptions, time in days is proportional to cumulative dose (Figure 3), hence in the
following modelling we will use cumulative dose and site specific cumulative dose.
Table 1 shows that no mucositis (0) is observed most often, followed by erythema, ulcer, con-
fluent ulcer and necrosis. Figure 2 shows frequencies of mucositis score by site and shows that
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Table 1: Collapsing the four level ordinal mucositis scores into binary scores using different cut
points r. Scores are no mucositis (0), erythema (1), ulcer (2), confluent ulcers (3) and necrosis
(4). The total number of n observations is due to 75 patients × 8 sites × 12.23 the mean number
of evaluations per patient.
mucositis score
cut point 0 1 2 3 4 n
none 3641 1616 1433 639 10 7339
r = 0 3641 3698 7339
r = 1 5257 2082 7339
r = 2 6690 649 7339
r = 3 7329 10 7339
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Figure 2: Left: Frequencies of mucositis scores by site. Scores no mucositis (0), erythema
(1), ulcer (2), confluent ulcers (3) and necrosis (4). Right: Boxplots of site specific median
cumulative dose for mucositis score 0 to 4.
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Figure 3: Cumulative dose versus time in days.
on the lower and upper lip high mucositis scores are rarer than at other sites. Figure 2 shows the
cumdos.sitei jl by site and mucositis score: upper and lower lip tend to receive the lowest lev-
els of site specific dose cumdos.sitei jl and mouth floor, tongue and soft palate tend to receive
the highest doses.
3 Biologically effective dose (BED)
Here we analyse physically cumulative dose. To eventually correct for repopulation we also
calculated the biologically effective dose (BED) using the so called αβ model, see for a review
Fowler [8]. Here we assume α
β
= 10Gy, where α and β are the coefficients for dose and dose2
in a linear model for cell kill. In the case of mucosa the α = 0.3Gy−1, the onset of accelerated
repopulation is 7 days and the average doubling time during accelerated repopulation is assumed
7
to be 2.5.
Figure 4 compares BED versus cumulative dose for each site. The straight lines, except for
some kinks, indicate that the two measures are proportional to each other. The kinks originate
from breaks in the radiation schedule due to strong side effects for some patients. These breaks
affect BED but not the cumulative dose.
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Figure 4: Cumulative dose vs. acute mucosa biological effective dose (BED).
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4 The flexible proportional odds model with random effects
As outlined in the introduction due to the complex data situation we require a model for an
ordinal multivariate outcome variable. In addition the model should be able to accommodate
the correlated repeated measures of individuals and should allow effects of continuous variables
to be non-linear, and we also want to test whether there is an interaction between site and site
specific dose.
4.1 The proportional odds model
The proportional odds model [11] addresses the first point, as it is a class of generalized linear
models used for modelling the dependence of an ordinal response on discrete or continuous
covariates. It can also be seen as an extension of a logistic regression model [4], as we could
model the mucositis scores collapsed into two categories for the two events Y ≤ r and Y > r as
shown in Table 1. But this leads to loss of efficiency, resulting in larger standard errors [1].
Let Yi denote the mucositis severity score in the range 0, ..., 4 for individual i. Then we model
the cumulative probability of Yi being less or equal to mucositis score r, P(Yi ≤ r) on the logit
scale. That is on the log scale of the (cumulative) odds of the event Yi ≤ r:
logit(P(Yi ≤ r)) = log P(Yi ≤ r)P(Yi > r) = αr − xiβ. (1)
On the logit scale the model is linear which makes it computationally convenient. In the above
example the xi is a continuous variable, e.g. cumulative dose. In the case of mucositis a plau-
sible way of constructing model 1 is to use the concept of an unobserved continuous response.
Suppose Ui is the unobserved mucositis severity on a continuous scale with Ui = xiβ + i. Al-
though we only observe the discrete mucositis scores, Yi = r is only observed if αr−1 < Ui ≤ αr.
The ”cut-points” αr are unknown points on the continuous mucositis severity scale. Lets also
assume that i = Ui − xiβ has a logistic distribution function F(.) with F(.) = exp(.)1+exp(.) then:
P(Yi ≤ r) = P(Ui ≤ αr) = P(Ui − xiβ ≤ αr − xiβ) = F(αr − xiβ)
and
P(Yi ≤ r) = exp(αr − xiβ)1 + exp(αr − xiβ)
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This model is mathematically equivalent to model 1. We also note the intuitive interpretation, if
β > 0 as xi increases also the P(Yi > r) increases. For example, as cumulative dose increases, it
is more likely that a high mucositis score is observed. In a model containing a linear effect for
cumdos.site the odds ratio of the event Y ≤ r for x1 = cumdos.site−10 and x2 = cumdos.site,
whilst keeping all other variables fixed, is
P(Yi ≤ r|x1)/P(Yi > r|x1)
P(Yi ≤ r|x2)/P(Yi > r|x2) = exp(−(x1 − x2)β) = exp((x2 − x1)β) = exp(10 β).
When using the same β across all categories, we assume that the odds ratio does not depend
on the category r, i.e. these cumulative odds are proportional across all categories. In a model
containing a factor variable for site based on the frequencies in Figure 2, this implies that the
cumulative odds of the events Y ≤ r, i.e. Y ≤ 0, Y ≤ 1, Y ≤ 2 and Y ≤ 3 by site are proportional
across all categories. For example, comparing the cumulative odds of mucositis in hard palate
versus soft palate is the same for all r:
P(Yi ≤ 0|hard)/P(Yi > 0|hard)
P(Yi ≤ 0|soft)/P(Yi > 0|soft) = ... =
P(Yi ≤ 2|hard)/P(Yi > 2|hard)
P(Yi ≤ 2|soft)/P(Yi > 2|soft)
4.2 A flexible multivariate random effects proportional odds model
In order to address all of the model requirements we extend the proportional odds model by
incorporating a multivariate response, random effects and non-linear functions of continuous
variables. This is an extension of the class of generalised additive mixed models [6, 16], because
the logistic distribution we are assuming for the latent response variable Ui and the error i does
not belong the exponential family. Below we introduce these different features step by step.
The model for individual i, assessment time index j, and site l is specified as
logit P(Yi jl ≤ r) = log P(Yi jl ≤ r)P(Yi jl > r) = αr − ηi jl
where
linear model: ηi jl = xTi jlβ + bi (2)
and Ui jl = ηi jl + i jl and i jl follows the logistic distribution. The xi jl is a row of the model matrix
containing the explanatory variables agei, studyi, sexi, cumdos.sitei jl, sitei, where sitei
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is a vector with dummy variables for the 8 sites and the parameter vector β contains the respec-
tive coefficients. We deal with the multivariate response, the mucositis scores assessed for eight
different mouth sites per patient and evaluation by including the factor sitei. This allows us
to test the null hypothesis that the effects of site are equal. As the dose specific to site is de-
termined by the tumour location, we adjust site estimates by site specific dose cumdos.sitei jl.
Individuals are observed repeatedly in time and within individual observations yi jl are correlated
in time and between locations and we account for this by introducing a random intercept bi for
individual i with bi ∼ N(0, σ2b). As we expect the dose-response relationship not to be linear,
we use a flexible function to model the effect of sites specific cumulative dose:
reduced model: ηi jl = xTi jlβ + f (cumdos.sitei jl) + bi (3)
the smooth function f is represented using a thin plate regression spline [16] with a penalty
based on the second derivative of the smooth function and now xTi jl = (agei, studyi, sexi,
siteTi ). The model above can be further extended. Besides testing whether sites effects differ,
we are also interested in testing whether the effect of site specific dose differs by site. For this
we introduce an interaction between site and site specific dose, by letting f vary by sitel:
full model: ηi jl = xTi jlβ + fl(cumdos.sitei jl) + bi. (4)
4.3 Parameter estimation
Inference can be based on Markov chain Monte Carlo (MCMC) [5, 2], on a mixed model ap-
proach using restricted maximum likelihood (REML) [10, 6, 17]. All of these are implemented
in the BayesX package [3, 14]. We present estimates using a Laplace approximation to REML
of Wood et al. [17], implemented in the gam() function of the R ([12]) package mgcv. In the
supplementary material we supply example R code for model fitting in both BayesX and in
mgcv.
Although the above reduced model (3) and the full model (4) include additive non-linear predic-
tors and random effects they can be expressed as a penalised generalised linear model (GLM);
ηi jl = xi jlθ, where xi jl is a row of the model matrix containing all components of the model; that
is, all strictly parametric components, such as explanatory variables of linear effects and the
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basis functions for non-linear predictors evaluated at observations i jl. The parameter vector θ
contains the coefficients of the basis functions and coefficients of linear terms and the cut-points
α1 to α4 . Note that for identifiability the first cut point α1 is set to -1.
The parameter estimation is an extended version of the nested iteration scheme described in
Wood [18]. Due to the ordered categorical response the scheme also needs to accommodate
the variable number of ordered cut points (here α1 to α4). The outer iteration is a Laplace
approximation marginal (restricted) maximum likelihood (LAML) estimation of smoothness
parameters and the cut points, where the coefficients of linear terms, and of basis functions
for the smooth terms of the parameter vector θ, are integrated out. The inner iteration is a
penalised iterative re-weighted least squares (PIRLS) algorithm to find all other parameters, i.e.
the coefficients of basis functions, and coefficients of linear terms. For details see Appendix F
in Wood et al. [17].
4.4 Model selection and validation
We consider the Akaike information criterion (AIC) and the Bayesian information criterion
(BIC)for model selection. The AIC is defined as AIC = −2l(θˆ) + 2ed f , the BIC is BIC =
−2l(θˆ) + log(n)ed f , where l is the conditional log likelihood given the penalised parameters,
ed f are the effective degrees of freedom, here estimated by the trace of the matrix that maps
the un-penalised estimates onto the penalised estimates corrected for the smoothing parameter
uncertainty as described in Wood et al. [17]; see also Greven and Kneib [9]. We also consider
the root mean square prediction error (RMSPE) estimated by cross-validation as a selection
criterion. For the cross-validation we leave out in turn each of 15 mutually exclusive sets of
patients and fit the model to the remaining patients data and predict the probabilities for the
outcomes, the mucositis scores. Having obtained predictions for each set of patients left out we
can estimate the root mean prediction error for each mucositis score.
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5 Results
In the modelling we combine the mucositis scores 3 (confluent ulcer) and 4 (necrosis) due
to the low frequencies of score 4. We start the model selection by reducing the complexity
of the full model (4). Table 5 gives an overview of the considered models and the results of
selection criteria are shown in Table 5. The most complex model is the full model (4) overall
has marginally the best goodness of fit, but with regards to parsimony the reduced model (3)
with the terms for age and sex removed comes out best. Hence the final selected model is
best model: ηi jl = α + β1studyi + site
T
iβ2 + f(cumdos.siteijl) + bi (5)
where β2 is the parameter vector for the 8 sites. Checking the residuals of the best model (5),
shows that the model fits well. The distributional assumptions of the model are correct, i.e.
the residuals follow a logistic distribution (Figure 5) and the random effects follow a normal
distribution (Figure 6). The assumption of proportional odds is adequate and has been checked
using diagnostic plots (not shown).
The model selection results also show that cumdos.site is by far the most important predictor,
followed by site. Results also show that effect of site specific cumulative dose is not linear, as
the goodness of fit is substantially reduced when the we use a linear effect for cumdos.site.
This is also apparent from the estimated smooth function of cumdos.site shown in Figure 6.
Replacing cumdos.site by BED in the full model (4), the reduced model (3) and the linear
model (2) does not improve the model fit. These models give an AIC of 15028.67, 15079.57
and 15085.05 respectively and the BIC values are 15726.93, 15658.66 and 15639.53. The
effect of cumdos.site is shown on the scale of the unobserved continuous mucositis score.
The cumulative dose has initially, up to approximately 20 Gy quite a strong effect on mucositis,
and this effect becomes weaker for > 20 Gy. There is a considerable amount of uncertainty
about the effect for high cumulative dosages. Figure 7 shows the cumulative odds of having a
score greater than r over having a score less or equal to r, with hard palate as the reference. e.g.:
P(Yi > r|soft)/P(Yi ≤ r|soft)
P(Yi > r|hard)/P(Yi ≤ r|hard) =
P(Yi ≤ r|hard)/P(Yi > r|hard)
P(Yi ≤ r|soft)/P(Yi > r|soft) = exp(0.185) = 1.171.
This shows that, after adjustment for cumulative radiation dose, upper, lower lip and mouth
13
floor are much less likely to have a higher mucositis score than the other sites. The site soft
palate is most likely to have a high score.
Table 2: Model overview given in ascending order regarding model complexity. The model
equation numbers are given in brackets. The xi jl is a row of the model matrix containing the
explanatory variables agei, studyi, sexi, cumdos.sitei jl, sitei, where sitei is a vector with
dummy variables for the 8 sites and the parameter vector β contains the respective coefficients.
model formula
linear model (2) ηi jl = xTi jlβ + bi
best model (5) ηi jl = α + β1studyi + site
T
iβ2 + f(cumdos.siteijl) + bi
reduced model (3) ηi jl = xTi jlβ + f (cumdos.sitei jl) + bi
full model (4) ηi jl = xTi jlβ + fl(cumdos.sitei jl) + bi
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Figure 5: Residual plots of the best model (5).
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Table 3: Model selection results. Shown are the effective degrees of freedom (edf), Akaike
information criterion (AIC), Bayes information criterion (BIC), root mean squared error for
predicting mucositis score 0 (RPE0), ... , 3 (RPE3) on the probability scale.
N edf AIC BIC RPE0 RPE1 RPE2 RPE3
full model (4) 7339 121.92 12185.50 13085.60 0.367 0.397 0.373 0.265
reduced model (3) 7339 84.71 12380.21 12989.66 0.371 0.398 0.374 0.265
linear model (2) 7339 78.38 13076.64 13639.67 0.380 0.401 0.375 0.272
linear model (2)
- cumdos.site 7339 77.76 15280.12 15835.42 0.455 0.407 0.390 0.278
reduced model (3) - site 7339 76.71 13284.12 13836.23 0.392 0.404 0.377 0.269
reduced model (3) - study 7339 85.05 12380.37 12992.07 0.373 0.398 0.374 0.267
reduced model (3) - age 7339 84.60 12380.17 12988.85 0.371 0.398 0.374 0.265
reduced model (3) - sex 7339 84.60 12380.17 12988.86 0.370 0.398 0.374 0.265
reduced model (3)
- sex - age 7339 84.48 12380.13 12988.03 0.370 0.398 0.374 0.265
reduced model (3)
- sex - age - study 7339 84.85 12380.29 12990.63 0.372 0.397 0.373 0.266
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Figure 6: Best model (5): Smooth (left) and qq-plot of the random intercepts for individuals
(right).
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Figure 7: Best model (5). Odds ratios of all the sites with 95% confidence/credible intervals
(left) and corresponding box-plots of cumulative doses applied to the eight sites (right). They
They are marked with gray dots by the cumulative doses when mucositis 3 or 4 first occurred.
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6 Discussion
In this observational study the radiotherapists made an effort to prevent much damage of mu-
cositis and randomized assignment of radiation dose for each site was not feasible. The assigned
dose has been carefully planned to avoid severe mucositis especially for what the practitioners
thought are the most vulnerable sites, upper and lower lip. Figure 2 confirms that the distribu-
tion of cumulative dose is not balanced among sites. In particular lower and upper lip and hard
palate obtain the lowest median cumulative doses of 7.2 to 10.3 Gy. The highest median doses
of 23.1 to 25.9 Gy arrive at soft palate, tongue and mouth floor. The left and right cheek have
median doses of 16.6 to 17.8 Gy. When we investigate the frequencies of the higher non-zero
mucositis scores by site in Figure 2, the same order is reflected. Upper and lower lip and hard
palate have the lowest frequencies of mucositis scores and soft palate receives the highest fre-
quencies of mucositis scores. If the dose was assigned to each site for each individual randomly,
it would have been possible to estimate the site effect without adjusting for (cumulative) dose.
However, the assigned dose has been carefully planned to avoid severe mucositis especially
for the most vulnerable sites, that is the sensitivity of sites and site specific cumulative dose
are confounded. For estimating the sensitivity of sites we need to adjust for cumulative dose
in a statistical model. The selected best model (5) contains site specific cumulative dose as a
non-linear effect, and the results show that after adjusting for site specific cumulative dose we
find that sensitivity to radiation varies by site. The upper and lower lip are, after adjusting for
cumulative dose, the least vulnerable to radiation, followed by mouth floor (Figure 7). More
vulnerable than the latter are the sites tongue, right and left cheek and most vulnerable to ra-
diation are soft and hard palate. We note that the ranking of sensitivity of sites is not in the
same order than if we just consider marginal frequencies of mucositis scores (Figure 2), due to
the confounding of cumulative dose with sites. On the boxplots of cumulative dose by site in
Figure 7 we have marked the cumulative dose when mucositis score 3 or 4 first occurred. This
shows that for upper and lower lip mucositis occurs rarely and at doses higher than those where
it occurs at other sites. We can also see that there is a good overlap in cumulative dose when
mucositis first occurred between sites.
Figure 8 compares the odds ratios of all sites from the best model (5) with the odds ratios
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from logistic regression models with the same terms as the best model (5), but having collapsed
the mucositis scores into a binary response using different values of r. For r = 0 the results
are similar, but the logistic regression model yields wider confidence intervals, for r = 1 and
r = 2 the confidence intervals from the logistic regression deviate substantially, and the answers
are not quite as clear cut as the confidence intervals overlap. This demonstrates that we loose
efficiency by aggregation.
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Figure 8: Odds ratios of all the sites with 95% confidence/credible intervals from the propor-
tional odds model (best model (5)) in gray. Overlaid are the corresponding confidence intervals
of odds ratios from logistic regression models with the same terms as the best model (5) having
collapsed the mucositis scores into a binary response using different values of r = 0, 1, 2 for the
two events Y ≤ r and Y > r as shown in Table 1. Note that we do not use r = 3, because in the
analysis we combined mucositis scores 3 and 4.
Our results depend on the accurate measurement of percentage median dose arriving at individ-
ual sites throughout the radiation schedule. It is also worth noting that we have not adjusted for
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the absolute volume of the sites in our model, but we assume that the volume does not differ
substantially between sites. It is future work to investigate whether site volume has an effect on
mucositis. In our analysis we have used cumulative dose rather than biological effective dose,
as the cumulative dose achieved the best model fit.
As in any statistical investigation, inference relies on the validity of the model. We have taken
great care to avoid model misspecification by using a flexible multivariate random effects pro-
portional odds model to estimate the effects. The model is complex, but this level of complexity
is required in order to reflect the data generating mechanism. We have carried out a thorough
model selection based on the AIC, BIC and the root mean square prediction error estimated by
15-fold cross-validation. The model deals with the repeated multivariate ordered categorical
outcome measures of individuals via random intercepts for individuals. The model also has
shown that the effect of cumulative dose is not linear, and that there is a possible interaction
between site and site specific dose, as we could not entirely reject the full model (4).
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